Member Info for Nolupus

TRek ,

Gilead is doing a very good PR job .....,.

Am awaiting the full data from their US trial which for the moment looks good ....

The rumors about the Roche drug is also very promising but will again need the data to confirm the rumeurs ....

Promising promising ..........not to be dismissed ...

Miggy,

You might not see things in the same light as Richard ....
Before going on a crusade, it might be worthwhile to ask him yourself :-)

Placebo placebo .....

Miggy,

Has it occurred to you that SNG might not appreciate the limelight ??

If they wanted publicity they are quite able to get as much as they like , imv

CAuldstream7,

You must be her number one fan :-)

Whilst her appointment to the CARE committee is good news one has to be factual ....
Her press statement after the initial P3 results brought a lot of criticism on the CNRS , and many have long memories :-)

This appointment might just spell the end of her ´ hibernation ´ , let's wait and see

It might be good for the Sp but it just might have an effect on the placebo patients :-)

Conducting trials under the radar has advantages !

Rumours are circulating on good results from the Roche il6 treatment against the cytokine storm patients which should help the speculation on TILS , next week , imo ........
Some good news is to be expected from the Sanofi camp as well :-)
So L1 with their ressources are always going to have the advantage ( L2 will follow a bit later :-). ).

All in my own opinion of course

TRek ,

As i have always said ....Not one miracle drug ... but many drugs will make up the puzzle of covid 19 treatment ....

I have a small investment in league 2 players like SNg and TIls but keeping my eyes centered on The L1 players :-)

You are now susceptible to be on the CIA radar .... Calling GIlead crooks ??
What's that all about ?

@ srrictlylîc

One protects ones capital first .... the best way is to use the ranges to sell/buy and eventually to leave the profits long term any take out the capital ....

With experience it becomes a reflex even though sometimes one can lose out but overall , it's a winning strategy

For veteran biotech investors , what you are saying makes a lot of sense ...

In the current situation many new investors have become interested and have invested their savings in covid19 stocks without really taking into account the risks involved ...imo

But what the heck , it's their money .....

Halfbutt,

Keep your eyes on the ball, and not on the people in the VIP box :-)

Formul,
I am very much aware of the last time that Sng ´rubbed shoulders ´ with Astra and how that finished ...
I don't expect that Richard would be inclined to ´ rub shoulders ´ with them again :-)

Hostile takeovers are very few and far between in the biotech world ....as we all. ( except blatant rampers ) know .

Guys,

Partnerships / takeovers take months of discussions and due diligence procedures so it's a bit early to be talking about this ... imo

Like us the majors will wait for trial data before instigating anything

Let's keep our eyes on the ball for the moment because the road is long

Two sides to every coin is my belief :-)

I have always said that interferon treatment should show good results in newly infected patients but I don't believe that the treatment will be effective in patients already in intensive care so this extension trial will help SNG to achieve a better overall score, imo

Not first at home ´ treatment ´ but maybe first at home drug ´ on trial

For your information, take a look at this

http://www.diazyme.com/covid-19-antibody-tests?from=singlemessage&isappinstalled=0

Yes Trek,
Everyone to their own trades and strategies ....
The problem with these boards is that too many people cannot accept decent honest discussions as they are ´ over exposed ´ ...... and are dreaming of multi bagging their investments and therefore not being a bit cautious with their capital, imv
Best of luck to you , as you are keeping your eyes on the ball in this rapidly changing environment

https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir-idUSKBN22B1T9

https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir-idUSKBN22B1T9

https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir-idUSKBN22B1T9